title: Can we win the war on obesity with pharmacotherapy?
abstract: Obesity is a major health concern for several countries. The United States (U.S.) has arguably led the world in the percentage of overweight and/or obese per capita for several decades. As a result, numerous FDA-approved pharmacotherapeutic options are available for the long-term treatment of obesity. Although most of these medications have been on the U.S. market for a few years and have demonstrated efficacy for long-term weight loss in clinical trials, the impact of these medications on obesity in the U.S. has yet to be realized. Areas covered: We will review and evaluate why pharmacotherapy for obesity has not produced a meaningful reduction in the number of overweight and obese adults in the U.S. Expert commentary: Several obstacles, such as adverse drug effects, poor insurance coverage, not treating obesity as a chronic disease, and availability of other weight loss alternatives, has resulted in poor performance of pharmacotherapy for obesity in the U.S. market.
authors: a Department of Animal Sciences, School of Environmental & Biological Sciences , Rutgers, The State University of New Jersey , New Brunswick , NJ , USA.|b Nutritional Sciences Graduate Program , Rutgers, The State University of New Jersey , New Brunswick , NJ , USA.
authors: Juliet D
authors: JD
authors: Gotthardt
authors: a Department of Animal Sciences, School of Environmental & Biological Sciences , Rutgers, The State University of New Jersey , New Brunswick , NJ , USA.|b Nutritional Sciences Graduate Program , Rutgers, The State University of New Jersey , New Brunswick , NJ , USA.|c New Jersey Institute for Food, Nutrition, and Health , Rutgers, The State University of New Jersey , New Brunswick , NJ , USA.
authors: Nicholas T
authors: NT
authors: Bello
keywords: Belviq; Contrave; Orlistat; Qsymia; Saxenda; liraglutide; lorcaserin; naltrexone/bupropion; phentermine/topiramate